The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > Cantab Pharmaceuticals plc

Cantab Pharmaceuticals plc
Nasdaq: CNTBE
Change
symbol:
     
 PROFILE
Cantab Pharma sings this song, gene vaccs, gene vaccs! Cantab Pharmaceuticals develops genetically engineered drugs and vaccines that stimulate patients' immune systems. Among the drug candidates in the firm's pipeline are melanoma treatment DISC-GMCSF; a vaccine for genital herpes it is developing with GlaxoSmithKline; and TA-HPV, a vaccine in development to treat cervical cancer. The firm has acquired the rights to vaccines aimed at nicotine and cocaine addictions. Cantab's other development partners include Celltech Group and Pfizer. Xenova Group, which focuses on developing cancer treatments, is buying the company.

 STOCK ANALYSIS
 View by:
 Day 
 Day 
 Month 
 Month 
 Year 
 Year 
FURTHER ANALYSIS
• Advanced Charting
• Deals

 FINANCIAL OVERVIEW
Fiscal Year-End: December
1999 Sales (mil.): 9.80
1-Yr. Sales Growth: 50.8%
Employees: 140
Revenue per employee: $70,000.00

 KEY PEOPLE
• Nicholas L. Hart
    CEO
• Nicholas L. Hart
    CFO

 CONTACT INFO
310 Cambridge Science Park
Cambridge CB4 0WG, United Kingdom
Phone: 44-1223-423-413
Fax: 44-1223-423-458
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001